Now that Twitter Inc. has raised its initial public offering (IPO) price range from a prior spread of $17 to $20 to a new range of $23 to $25 there remain plenty of analysts who think that is a justifiable number. Counting outstanding shares of restricted stock and options, the company will have nearly 695 million shares out in the world and at the mid-point of the new range the company would be valued at $13.6 billion.
How does that stack up with some other IPOs in the tech world? Financial analysis firm Sageworks Inc. has prepared a handy chart comparing Twitter�� pending IPO with those of Facebook Inc. (NASDAQ: FB), Microsoft Corp. (NASDAQ: MSFT), and Apple Inc. (NASDAQ: AAPL). Apple went public in 1980, Microsoft in 1985, and Facebook just last year. In the following chart, Sageworks uses the number of Class A common shares outstanding to compute Twitter�� valuation.
Source: Sageworks Inc.
Top 10 Up And Coming Stocks For 2015: Cornerstone Strategic Value Fund Inc (CLM)
Cornerstone Strategic Value Fund, Inc. (the Fund), incorporated on May 1, 1987, is a closed-end, diversified management investment company. The Fund invests in equity securities of companies listed in the United States. Cornerstone Strategic Value Fund, Inc. invests in various sectors, which include financials, information technology, healthcare, consumer discretionary, industrials, consumer staples, energy, utilities, telecommunication services, materials and other sectors.
As of December 31, 2005, the Fund's top 10 holdings were General Electric Co., Exxon Mobil Corp., Microsoft Corp., Citigroup Inc., Procter & Gamble Co. (The), EMC Corp., Bank of America Corp., American International Group, Inc., Johnson & Johnson and Pfizer Inc. Cornerstone Strategic Value Fund, Inc.'s investment manager is Cornerstone Advisors, Inc.
Advisors' Opinion:- [By Dividends4Life]
According to a Gabelli Funds report, managed distribution policies offer several advantages, including:1. Lower difference between the fund�� market price and its NAV per share.2. Provides support during periods when the stock market is in a decline.3. Provides a measurable performance target for the investment adviser.Below are several high-yield funds from CEFA that have a managed distribution policy (yields as of December 16):Aberdeen Australia Eqty (IAF)- Distribution Yield: 10.4%- Income Yield: 3.46%Bexil Advisers LLC� (DNI)- Distribution Yield: 11.1%- Income Yield: 3.56%BlackRock En Capital&Inc (CII)- Distribution Yield: 8.78%- Income Yield: 2.34%Cornerstone Strat Value (CLM)- Distribution Yield: 18.77%- Income Yield: 1.83%Cornerstone Total Return (CRF)- Distribution Yield: 19.10%- Income Yield: 0.85%Delaware Inv Div & Inc (DDF)- Distribution Yield: 6.70%- Income Yield: 5.26%Gabelli Equity Trust (GAB)- Distribution Yield: 7.58%- Income Yield: 1.54%Gabelli Utility Trust (GUT)- Distribution Yield: 9.45%- Income Yield: 2.84%MFS Special Value Trust (MFV)- Distribution Yield: 9.60%- Income Yield: 5.73%Nuveen Tx-Adv TR Strat (JTA)- Distribution Yield: 6.70%- Income Yield: 3.12%TCW Strategic Income (TSI)- Distribution Yield: 10.54%- Income Yield: 7.88%Zweig Total Return (ZTR)- Distribution Yield: 7.27%- Income Yield: 1.95%As noted in the Gabelli report, a managed distribution policy may create confusion regarding the true current yield since the reported yield includes the return of capital portion. You can see the disparity above between the income yield and the distribution (reported) yield.If you are looking for a sustainable and growing dividend, you may want to consider some blue-chip dividend stocks such as these with a Free Cash Flow Payout less than 50%, 50+ years of consecutive dividend increases and a 2%+ yield:3M Co. (MMM) is a diversified global company provides enhanced product functionality in electronics, health care, industrial, consumer
Best Electric Utility Stocks To Invest In 2014: Australia and New Zealand Banking Group Ltd (ANZ)
Australia and New Zealand Banking Group Limited (ANZ) provides a range of banking and financial products and services to retail, small business, corporate and institutional clients. The Company conducts its operations in Australia, New Zealand and the Asia Pacific region. It also operates in a range of other countries, including the United Kingdom and the United States. The Company operates on a divisional structure with Australia, International and Institutional Banking (IIB), New Zealand, and Global Wealth and Private Banking. As of September 30, 2012, the Company had 1,337 branches and other points of representation worldwide, excluding automatic teller machines (ATMs). In September 2012, it sold its remaining shareholding in Visa Inc. Advisors' Opinion:- [By Weiyi Lim]
The funds lured a net $25.9 billion in the period, Wei Liang Chang, a foreign-exchange strategist at Australia & New Zealand Banking Group Ltd. (ANZ), said by phone from Singapore today, citing data from EPFR Global. Developed markets posted $24.3 billion of inflows, while emerging-nation funds drew $1.6 billion, according to Chang.
- [By Adam Haigh]
Komatsu Ltd. tumbled 8 percent in Tokyo after the world�� second-largest maker of construction equipment cut its full-year profit forecast by 26 percent. Industrial & Commercial Bank of China Ltd. gained 1.4 percent in Hong Kong, pacing an advance among Chinese lenders, after China�� central bank added funds to the financial system for the first time in two weeks. Australia & New Zealand Banking Group Ltd. (ANZ) climbed 1.4 percent to a record in Sydney after posting its highest profit and raising its dividend more than forecast.
Best Electric Utility Stocks To Invest In 2014: iStar Financial Inc.(SFI)
iStar Financial Inc. operates as a finance company focusing on the commercial real estate industry. The company provides custom-tailored financing to high-end private and corporate owners of real estate. Its financing products include senior and mezzanine real estate debt, senior and mezzanine corporate capital, corporate net lease financing, and equity. The company also involves in corporate tenant leasing business, which provides capital to corporations and others who control facilities leased primarily to single creditworthy customers. As of December 31, 2008, iStar Financial owned 362 office, industrial, entertainment, hotel, and retail facilities in 39 states. The company qualifies as a REIT for federal income tax purposes. As a REIT, it generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 1993 and is based in New York, New York.
Advisors' Opinion:- [By Sally Jones]
iStar Financial Inc. (SFI): Sold OutUp 52% over 12 months, iStar Financial has a market cap of $940.1 million and trades with a P/B of 0.70. The current share price is $11.01.
Best Electric Utility Stocks To Invest In 2014: Geron Corporation (GERN)
Geron Corporation, a biopharmaceutical company, develops therapies for cancer. Its clinical development product candidates include Imetelstat, a telomerase inhibitor, which is in Phase II clinical trials for the treatment of metastatic breast cancer, advanced non-small cell lung cancer, thrombocythemia, and myeloma. The company was founded in 1990 and is based in Menlo Park, California.
Advisors' Opinion:- [By John Udovich]
On Tuesday, small cap biopharmaceutical company Epizyme Inc (NASDAQ: EPZM) surged 75.56% after the company announced that its�EPZ-5676, a DOT1L inhibitor for acute leukemias, had reached its proof-of-concept milestone, meaning its worth taking a closer look at the stock as well as look at the share performance of cancer stocks like large cap Celgene Corporation (NASDAQ: CELG) and small caps�Dendreon Corporation (NASDAQ: DNDN) and Geron Corporation (NASDAQ: GERN).
- [By Paul Ausick]
Stocks on the Move: Veeva Systems Inc. (NYSE: VEEV) is up a whopping 85.5% at $37.15 on huge demand following its IPO. Geron Corp. (NYSE: GERN) is up 39.7% at $4.37. Molycorp Inc. (NYSE: MCP) is down 1.8% at $5.48 following a secondary stock offering.
- [By Paul Ausick]
Stocks on the Move: Twitter Inc. (NYSE: TWIT) opened at $45.10, about 70% higher than its IPO price of $26, but posted only a small gain to close at $44.94, down 0.42%, after hitting $50.09 early in the day. Geron Corp. (NASDAQ: GERN) is up 44.8% at $5.21 following a good report on its myelofibrosis drug.
- [By Jake L'Ecuyer]
Equities Trading DOWN
Shares of Geron (NASDAQ: GERN) were down 18.46 percent to $4.5828 after the company reported that 20 patients have discontinued from Imetelstat study since its inception.
Best Electric Utility Stocks To Invest In 2014: Seattle Genetics Inc.(SGEN)
Seattle Genetics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases in the United States. Its lead product, SGN-35 is in pivotal trial stage used for the treatment of patients with relapsed or refractory hodgkin lymphoma. The company?s other product candidates in various stages of clinical trials include SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; dacetuzumab (SGN-40), a humanized anti-CD40 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc .; Daiichi Sankyo Co., Ltd.; Genentech, Inc.; GlaxoSmithKline LLC; Millennium; and PSMA Development Company LLC. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc.; and Genmab A/S. Seattle Genetics, Inc. was founded in 1997 and is headquartered in Bothell, Washington.
Advisors' Opinion:- [By Brian Orelli]
It's certainly in the FDA's right to ask outside experts for their opinion; I would argue it's not all that surprising even if the FDA is leaning strongly toward approving the drug. There are plenty of cases --�Seattle Genetics' (NASDAQ: SGEN ) Adcetris,�for example�--�where the FDA called a meeting only to gush all over the drug. The drug got a unanimous positive recommendation from the panel and was approved early by the FDA.
- [By Motley Fool Staff]
Whether it's in the abstract or at the meeting, I'm looking forward to seeing Seattle Genetics' (NASDAQ: SGEN ) data from its Aethera trial, testing Adcetris immediately following an autologous stem cell transplantation in patients with Hodgkin lymphoma. The biotech already reported a 75% improvement in progression-free survival -- living without the disease progressing -- but the details of how the patients are responding are more important than the top-line data.
- [By Henry Kawabe]
One of the variables that differentiates SMDCs from another cancer treatment in development, like Seattle Genetics' (SGEN) antibody-drug conjugates (ADC), are that SMDCs are 100-150 times smaller than an antibody. These small conjugates are able to penetrate solid tumors more effectively than large molecules ADCs. In preclinical studies, Endocyte saw a 20 to 30 fold improvement in drug concentration inside solid tumors with small molecule drug conjugates compared to large molecule drug conjugates. The small size also demonstrated faster excretion, which helped to reduce the drug's toxicity.
- [By Brian Orelli]
Seattle Genetics (NASDAQ: SGEN ) is up in after-hours trading after posting record sales for its blood cancer drug Adcetris, and raising guidance for the year. The biotech sold $48 million worth of Adcetris in the U.S. and Canada, a 32% year-over-year increase.
No comments:
Post a Comment